using machine learning to predict the outcomes of patients with ndmm being treated with vrd
Published 11 months ago • 57 plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
2:12
using a novel machine learning model to analyze and predict the outcomes of patients with ndmm
-
1:34
single-center study evaluating the outcomes of patients with aml who relapsed after allosct
-
2:16
cpx-351 in poor risk aml patients
-
2:29
cpx-351 vs 7 3 in older high-risk aml patients
-
3:31
update on quantum-first: quizartinib soc chemotherapy & as continuation therapy in flt3-itd aml
-
1:39
quantum-first: flt3-itd-specific mrd clearance is associated with improved os in newly diagnosed aml
-
1:05
using whole genome sequencing to identify novel predictors for sct in patients with mds
-
1:07
quantum-first: the benefit of quizartinib based on pre-transplant mrd status
-
7:36
quantum therapy five days class (nov15 - nov19)
-
34:35
enp65: type 1 diabetes and challenges across the lifespan
-
11:06
how could new treatment options improve outcomes in flt3-mutated aml?
-
2:35
quizartinib for frontline flt3-itd aml: updated results from the quantum-first trial
-
2:54
quantum-first: association between flt3-itd-specific mrd clearance and survival in patients with aml
-
3:03
ongoing challenges and unanswered questions in the field of aml
-
0:57
potential approval of quizartinib in aml & its place in the aml treatment regimen
-
2:20
quantifying the anemia benefit of momelotinib in mf: analysis of data from simplify-1 & simplify-2
-
4:09
quantum-r: quizartinib looks promising for flt3-itd mutated aml
-
2:47
using artificial intelligence to estimate overall mortality and non-relapse mortality after allosct
-
1:27
unmet needs and future questions in cellular therapy for myeloma
-
1:13
updated overall survival findings from the phase iii intrigue trial
-
1:04
dr. levis on quizartinib in aml patients without the flt3-itd mutation
-
1:18
dr. levis discusses the ideal use of quizartinib in flt3-itd aml